drugset
drugset / Trial / NCT06176040

A Study of TAVO101 in Atopic Dermatitis Patients

NCT06176040 ↗

Phase 2 Active not recruiting 20 enrolled Tavotek Biotherapeutics
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.

Timeline

Start
2024-03-15
Primary completion
2025-03-15
Completion
2025-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject TAVO101 Unknown — Intravenous

Indications

atopic eczema